Compositions for topical treatment and their use in the manufacture of medicaments
CN122097356APending Publication Date: 2026-05-29AFT PHARM LTD
View PDF 1 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- AFT PHARM LTD
- Filing Date
- 2021-11-04
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
Rapamycin is prone to chemical degradation during storage, leading to insufficient drug strength.
Method used
A composition using 0.5 wt% to 5 wt% rapamycin, 12 wt% to 16 wt% glyceryl monolaurate and 12 wt% to 16 wt% glyceryl monomyristate as carriers and water as solvent is used for topical treatment to form multilayer undissolved or suspended particles with particle sizes ranging from 1 µm to 100 µm.
Benefits of technology
It significantly improves the stability and efficacy of rapamycin, especially at high concentrations, exhibiting excellent storage stability and skin absorption permeability, making it suitable for the treatment of angiofibroma, cutaneous vascular lesions, and port-wine stains.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122097356A_ABST
Abstract
Rapamycin is a known pharmaceutical therapeutic substance. One problem with rapamycin is that it is very unstable and prone to chemical degradation during storage. This can result in the drug becoming "under strength" within the shelf life. It is an object of the present invention to at least partially address this problem. Disclosed is a composition for topical treatment and its use in the manufacture of a medicament, comprising rapamycin as an active ingredient; a carrier comprising glyceryl monolaurate and glyceryl monomyristate; and water as a solvent.
Need to check novelty before this filing date? Find Prior Art